Skip to main content
  • Poster presentation
  • Open access
  • Published:

The effects of super-flux (high performance) dialyzer on the plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis

Background

The current BNP immunoassay cross-reacts with glycosylated proBNP, and the NT-proBNP assay underestimates glycosylated NT-proBNP. In addition, the recently developed high performance dialyzer removes medium-sized molecular solutes such as β2-microgloburin. We therefore investigated the effects of high performance dialysis on measured levels of glycosylated proBNP, glycosylated NT-proBNP and other BNP-related peptides in end-stage renal disease (ESRD) patients on hemodialysis.

Method

We used our newly developed immunoassay to measure plasma total BNP, proBNP and mature BNP in 36 ESRD patients before and after hemodialysis. Plasma glycosylated NT-proBNP and nonglycosylated NT-proBNP were measured using Elecsys II after treatment with the deglycosylating enzymes neuramoinidase and O-glycosydase. We also measured plasma ANP and cGMP using radioimmunoassays.

Results

Total BNP (-38.9%), proBNP (-29.7%), mature BNP (-54%), glycosylated NT-proBNP(-45.5%), nonglycosylated NT-proBNP(-53.4%), ANP(-50.4%) and cGMP(-72.1%) were all significantly reduced after hemodialysis. The relative magnitudes of the reductions did not correlate with any indices of plasma volume, but instead appeared to be molecular weight dependent. The proBNP/total BNP and glycosylated NT-proBNP/nonglycosylated NT-proBNP ratios were increased after hemodialysis. The proBNP/total BNP ratio correlated positively with hemodialysis vintage and negatively with left atrial diameter and systolic blood pressure, whereas glycosylated/nonglycosylated NT-proBNP ratios correlated positively with parathyroid hormone levels.

Conclusion

These results suggest that plasma BNP and its related peptides measured immediately after hemodialysis may not be good indices of body fluid status in ESRD patients undergoing hemodialysis using a high performance dialyzer. ProBNP/total BNP may be influenced by hemodialysis vintage, cardiac afterload and diastolic function.

References

  1. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, Nakagawa Y, Kinoshita H, Yamada C, Nakao K, Minami T, Kuwabara Y, Kuwahara K, Masuda I, Kangawa K, Minamino N, Nakao K: Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PLoS One. 2013, 8: e53233-10.1371/journal.pone.0053233.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshio Nishikimi.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Nakagawa, Y., Nishikimi, T., Minamino, N. et al. The effects of super-flux (high performance) dialyzer on the plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis. BMC Pharmacol Toxicol 14 (Suppl 1), P47 (2013). https://doi.org/10.1186/2050-6511-14-S1-P47

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2050-6511-14-S1-P47

Keywords